🚀 VC round data is live in beta, check it out!
Keqian Biology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Keqian Biology and similar public comparables like SPIMACO - ADDWAEIH, Gen İlaç, SanBio, CytomX Therapeutics and more.
Keqian Biology Overview
About Keqian Biology
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
Founded
2001
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$781M
Keqian Biology Financials
Keqian Biology reported last 12-month revenue of $144M and EBITDA of $80M.
In the same LTM period, Keqian Biology generated $97M in gross profit, $80M in EBITDA, and $62M in net income.
Revenue (LTM)
Keqian Biology P&L
In the most recent fiscal year, Keqian Biology reported revenue of $139M and EBITDA of $87M.
Keqian Biology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $144M | XXX | $139M | XXX | XXX | XXX |
| Gross Profit | $97M | XXX | $93M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $80M | XXX | $87M | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 62% | XXX | XXX | XXX |
| EBIT Margin | 50% | XXX | 51% | XXX | XXX | XXX |
| Net Profit | $62M | XXX | $61M | XXX | XXX | XXX |
| Net Margin | 43% | XXX | 44% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Keqian Biology Stock Performance
Keqian Biology has current market cap of $1B, and enterprise value of $781M.
Market Cap Evolution
Keqian Biology's stock price is $2.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $781M | $1B | -0.8% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKeqian Biology Valuation Multiples
Keqian Biology trades at 5.4x EV/Revenue multiple, and 9.7x EV/EBITDA.
EV / Revenue (LTM)
Keqian Biology Financial Valuation Multiples
As of April 18, 2026, Keqian Biology has market cap of $1B and EV of $781M.
Equity research analysts estimate Keqian Biology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Keqian Biology has a P/E ratio of 16.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $781M | XXX | $781M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 8.4x | XXX | XXX | XXX |
| P/E | 16.6x | XXX | 16.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 15.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Keqian Biology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Keqian Biology Margins & Growth Rates
Keqian Biology's revenue in the last 12 month grew by 11%.
Keqian Biology's rule of 40 is 68% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Keqian Biology's rule of X is 84% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Keqian Biology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 68% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 84% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Keqian Biology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| SPIMACO - ADDWAEIH | XXX | XXX | XXX | XXX | XXX | XXX |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| SanBio | XXX | XXX | XXX | XXX | XXX | XXX |
| CytomX Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MedinCell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keqian Biology M&A Activity
Keqian Biology acquired XXX companies to date.
Last acquisition by Keqian Biology was on XXXXXXXX, XXXXX. Keqian Biology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Keqian Biology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKeqian Biology Investment Activity
Keqian Biology invested in XXX companies to date.
Keqian Biology made its latest investment on XXXXXXXX, XXXXX. Keqian Biology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Keqian Biology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Keqian Biology
| When was Keqian Biology founded? | Keqian Biology was founded in 2001. |
| Where is Keqian Biology headquartered? | Keqian Biology is headquartered in China. |
| Is Keqian Biology publicly listed? | Yes, Keqian Biology is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Keqian Biology? | Keqian Biology trades under 688526 ticker. |
| When did Keqian Biology go public? | Keqian Biology went public in 2020. |
| Who are competitors of Keqian Biology? | Keqian Biology main competitors are SPIMACO - ADDWAEIH, Gen İlaç, SanBio, CytomX Therapeutics. |
| What is the current market cap of Keqian Biology? | Keqian Biology's current market cap is $1B. |
| What is the current revenue of Keqian Biology? | Keqian Biology's last 12 months revenue is $144M. |
| What is the current revenue growth of Keqian Biology? | Keqian Biology revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Keqian Biology? | Current revenue multiple of Keqian Biology is 5.4x. |
| Is Keqian Biology profitable? | Yes, Keqian Biology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Keqian Biology? | Keqian Biology's last 12 months EBITDA is $80M. |
| What is Keqian Biology's EBITDA margin? | Keqian Biology's last 12 months EBITDA margin is 56%. |
| What is the current EV/EBITDA multiple of Keqian Biology? | Current EBITDA multiple of Keqian Biology is 9.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.